U.S. markets open in 5 hours 52 minutes

FluroTech Ltd. (FLURF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.4000-0.0975 (-19.60%)
At close: 3:41PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4975
Open0.5530
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.4000 - 0.5530
52 Week Range0.0493 - 0.6819
Volume63,479
Avg. Volume70,399
Market Cap30.245M
Beta (5Y Monthly)-1.31
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • FluroTech Partners With Toolbox Medical Innovations for Clinical Trial of Mass-Scale COVID-19 Testing Platform
      GlobeNewswire

      FluroTech Partners With Toolbox Medical Innovations for Clinical Trial of Mass-Scale COVID-19 Testing Platform

      CALGARY, Alberta, March 04, 2021 (GLOBE NEWSWIRE) -- FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) (“FluroTech” or the “Company”), a leading developer of spectroscopy-based technology, together with joint venture FluroTest, LLC (“FluroTest”), a first-mover in surge-scale rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, are pleased to announce that an agreement with Toolbox Medical Innovations (“Toolbox”) has been signed this week to carry out clinical trials of the FluroTest pandemic response platform alongside a comparator RT-PCR assay for performance detection of SARS-CoV-2 in saliva samples. Toolbox Medical Innovations is an ISO 13485-certified consumables development firm and a full contract research organization (CRO) specializing in needs of the point-of-care diagnostic and life science industry. With a network consisting of over 100 clinical sites and over 50 combined years of clinical research and regulatory support, IVD product engineering and medical device usability testing experience, Toolbox is well-versed in simplifying and expediting the complex FDA approval procedures. Toolbox has a profound expertise in helping organizations surpass each step of the submission process from clinical study design and development, all the way up to regulatory planning and support, allowing them to provide a fast and efficient path to FDA and other approvals for IVD diagnostic products. FluroTest will employ its pre-production testing platform developed with its partner Hudson Robotics. FluroTest is aiming to enroll approximately 600 volunteer participants, including both symptomatic and asymptomatic individuals. The clinical trials are anticipated to begin by mid-April. The data collected will be used to support FluroTest’s submission for Emergency Use Authorization (“EUA”) from the U.S. Food and Drug Administration (“FDA”) and Health Canada for an Interim Order Authorization. Future submissions to additional regulatory bodies around the globe are also being considered. “We continue to take measured steps in our execution and remain laser-focused on our objectives. This is a significant point in our path forward and we aim to ensure a smooth, timely, and accurate process,” said Bill Phelan, CEO of FluroTest. “Partnering with Toolbox allows us to leverage decades of clinical trial experience with professionals who have organized and executed clinical studies for Ellume and LumiraDx which have secured FDA EUA status. The goal of 600 participants, utilizing multiple clinical research institutions throughout North America, exceeds regulatory requirements. Suffice it to say our confidence and commitment to product validation remain strong. We believe the data endpoints will reflect favorably for our submission.” “We are proud to bring decades of clinical trial, useability testing, regulatory and manufacturing experience to bear as we partner with FluroTest to conduct these clinical trials.” noted John Zeis, President of Toolbox Medical Innovations. “Enabling people to congregate in large venues such as stadiums, arenas, and large corporate environments safely and securely is critical to opening our economy. We are proud to be conducting clinical trials focused on enabling this.” “With numerous research studies and trials to date, Toolbox is dedicated to bettering the medical community and enhancing population health. This dedication will ensure a stringent evaluation of our technology for the detection of the SARS-CoV-2 antigen in a clinical laboratory environment,” added FluroTech R&D Director and Senior Scientist, Dr. Mauricio Arias. “In collaboration with Toolbox’s research team, our clinical study is designed to surpass current FDA requirements for Emergency Use Authorization and is structured to demonstrate the efficacy of our antigen detection technology.” Readers are cautioned that, although FluroTest has achieved proof of concept prototype, the testing method and device is still in the early stages of research and development and accordingly FluroTest is not currently making any express or implied claims that the technology can, or will be able to, accurately detect the COVID-19 virus. The Platform is in the process of applying for EUA approval from the FDA and Health Canada for an Interim Order Authorization. About FluroTech (TSXV: TEST) (OTCQB: FLURF) The goal of FluroTech’s research and technology is to develop detection methods which are sensitive, specific and easy-to-use. By combining FluroTech’s proprietary spectroscopy-based technology with laboratory robotics automation and cloud computing, FluroTech, through the application of its technology and investment in FluroTest, has created a unique solution addressing the current and future pandemics. Using technology that was first developed at the University of Calgary, the FluroTest SARS-CoV-2 test is designed to identify patients with active virus infection; this is not necessarily the case for most of the currently approved tests that are meant to identify patients with SARS-CoV-2 nucleic acid. FluroTech’s laboratory is led by Dr. Elmar Prenner, the original developer of the technology. Dr. Prenner serves as senior science advisor of FluroTech and brings over 28 years of expertise in fluorescence spectroscopy. To learn more, visit FluroTech.com About FluroTest LLC FluroTest, a first-mover in surge-scale rapid antigen testing for the detection of SARS-CoV2 and other pathogens, is developing a pandemic defense and economic recovery system purpose-built for businesses and special-needs populations requiring fast and highly accurate testing for significant numbers of people. Unlike individual or low-throughput tests, FluroTest’s system is designed to be well-suited for high-traffic, high-risk pandemic environments including schools and colleges, hospitals and large healthcare facilities, athletic stadiums and performance venues, airline and cruise ship terminals, corporate campuses, shopping centers, manufacturing facilities, transportation and distribution hubs and other large business and retail locations. Created to support executive business continuity efforts, the system combines and leverages the disciplines of robotics automation, biochemistry, fluorescence detection and cloud computing -- processing thousands of tests per hour while delivering accurate, digitally verifiable results to a test taker’s mobile device within 5 minutes. To learn more, visit FluroTest.com For all investor inquiries: MarketSmart Communications Inc. 1-877-261-4466 Info@marketsmart.ca For general inquiries: FluroTech Ltd. Danny Dalla-Longa Chief Executive Officer 403.680.0644 info@flurotest.com Cautionary Statement Regarding Forward-Looking Information This news release contains "forward-looking information" within the meaning of Canadian securities legislation. Forward-looking information generally refers to information about an issuer’s business, capital, technology or operations that is prospective in nature, and includes future-oriented financial information about the issuer’s prospective financial performance or financial position. The forward-looking information in this news release includes disclosure about the ability of the Company’s testing devices to accurately and quickly detect COVID-19 and to process large numbers of samples in short time frames, the benefits of and demand for the Company’s testing devices, its efforts to obtain approval of the FDA and Health Canada, its potential partnership with a major U.S. based healthcare system and finalizing plans to conduct clinical trials and its intent to amalgamate with FluroTest Systems Ltd which owns a 95% interest in FluroTest LLC. The Company made certain material assumptions, including but not limited to prevailing market conditions and general business, economic, competitive, political and social uncertainties, the ability to obtain FDA and Health Canada approvals, the demand for its COVID-19 testing devices and their ability to perform as expected, its potential partnership with a major U.S. based healthcare system and finalizing plans to conduct clinical trials and its intent to amalgamate with FluroTest Systems Ltd which owns a 95% interest in FluorTest LLC and to obtain the regulatory approvals required in connection with the same, to develop the forward-looking information in this news release. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Actual results may vary from the forward-looking information in this news release due to certain material risk factors described in the Corporation’s Annual Information Form under the heading “Risk Factors”, the failure to develop and commercialize its testing devices in a timely manner or at all, the failure to recognize the anticipated benefits from the devices, the failure to obtain FDA or Health Canada approval for its products, the risk that regulatory approvals will not be received and the risk that changing circumstances will result in the decrease in demand for FluroTest’s products. The Company cautions that the foregoing list of material risk factors and assumptions is not exhaustive. The Company assumes no obligation to update or revise the forward-looking information in this news release, unless it is required to do so under Canadian securities legislation. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or the securities laws of any state and may not be offered or sold within the United States or to or for the benefit or account of U.S. persons, absent such registration or an applicable exemption from such registration requirements.

    • Robotics Automation Pioneer Phillip Farrelly Joins Flurotech Scientific Advisory Board
      GlobeNewswire

      Robotics Automation Pioneer Phillip Farrelly Joins Flurotech Scientific Advisory Board

      CALGARY, Alberta, March 01, 2021 (GLOBE NEWSWIRE) -- FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) (“FluroTech” or the “Company”), a leading developer of spectroscopy-based technology, together with joint venture partner FluroTest, LLC (“FluroTest”), a first-mover in surge-scale rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today announced that visionary inventor and Hudson Robotics Founder and President Phil Farrelly has joined FluroTech’s advisory board. Mr. Farrelly is a noted life sciences and lab automation authority and innovator. He founded Hudson Robotics in 1983, establishing the company as a market leader in microplate automation, laboratory robotics, liquid handling and customized software-driven laboratory automation solutions for life sciences research. The company develops specialized tools used in areas such as drug discovery, clinical research and pharmaceutical development, including high throughput screening, proteomics and genomics. A strategic partnership with FluroTest was announced November 20, 2020 and, most recently, pre-production development of three functioning pandemic defense platform systems were announced on February 19, 2021. “I’ve dedicated much of my adult life to advancing the science of automation, and in the wake of one of the worst global economic downturns in recent history, I believe manufacturing technologies that increase throughput, productivity, accuracy and safety have never been more important,” said Farrelly. “The FluroTest Pandemic Defense System is a seriously innovative way to approach a problem that will be with us for years to come. I am excited to support their efforts as an advisor.” “Hudson Robotics is well recognized as a leading innovator and we are fortunate to be working closely with such a great partner. I’m beyond thrilled to have a robotics automation icon like Phil Farrelly personally interested and actively involved in our testing platform,” said Bill Phelan, CEO of FluroTest. “Phil is a proven expert, and his expertise and insight will be invaluable as we move toward commercial availability.” FluroTest’s system is designed to be portable and to facilitate point-of-service, rapid testing of individuals with high-speed, high throughput functionality. Target industries include schools and colleges, hospitals and large healthcare facilities, athletic stadiums and performance venues, airline and cruise ship terminals, corporate campuses, shopping centers, manufacturing facilities, transportation and distribution hubs and other large business and retail locations. “We need rapid results delivery, not more rapid test talk,” added Danny Dalla-Longa, CEO of FluroTech. “Our automated testing system is designed to cater to the masses and deliver test results in minutes. We’re now seeing some stadiums doubling up as vaccination sites, and I believe it’s only a matter of time before automated rapid testing applications follow suit. With Phil Farrelly and Hudson Robotics as additions to the team, we’re one big step closer to our goal of processing thousands of tests per hour while delivering digitally verifiable results to a test taker’s mobile phone within minutes.” Readers are cautioned that, although FluroTest has achieved proof of concept prototype, the testing method and device is still in the early stages of research and development; accordingly, FluroTest is not currently making any express or implied claims that the technology can, or will be able to, accurately detect the COVID-19 virus. The Platform is in the process of applying for EUA approval from the FDA and for an Interim Order Authorization from Health Canada. As announced February 3, 2021 FluroTech has accelerated the financial, regulatory and legal due diligence to complete the transaction with FluroTest shareholders to obtain 95% of the interest in FluroTest. This amalgamation is subject to TSXV conditions and approvals. FluroTech is working to ensure this process is carried out in the most efficient manner possible and will update the market as appropriate. About FluroTech (TSXV: TEST) (OTCQB: FLURF) The goal of FluroTech’s research and technology is to develop detection methods which are sensitive, specific and easy-to-use. By combining FluroTech’s proprietary spectroscopy-based technology with laboratory robotics automation and cloud computing, FluroTech, through the application of its technology and investment in FluroTest, has created a unique solution addressing the current and future pandemics. Using technology that was first developed at the University of Calgary, the FluroTest SARS-CoV-2 test is designed to identify patients with active virus infection; this is not necessarily the case for most of the currently approved tests that are meant to identify patients with SARS-CoV-2 nucleic acid. FluroTech’s laboratory is led by Dr. Elmar Prenner, the original developer of the technology. Dr. Prenner serves as senior science advisor of FluroTech and brings over 28 years of expertise in fluorescence spectroscopy. To learn more, visit FluroTech.com About FluroTest LLC FluroTest, a first-mover in surge-scale rapid antigen testing for the detection of SARS-CoV2 and other pathogens, is developing a pandemic defense and economic recovery system purpose-built for businesses and special-needs populations requiring fast and highly accurate testing for significant numbers of people. Unlike individual or low-throughput tests, FluroTest’s system is designed to be well-suited for high-traffic, high-risk pandemic environments including schools and colleges, hospitals and large healthcare facilities, athletic stadiums and performance venues, airline and cruise ship terminals, corporate campuses, shopping centers, manufacturing facilities, transportation and distribution hubs and other large business and retail locations. Created to support executive business continuity efforts, the system combines and leverages the disciplines of robotics automation, biochemistry, fluorescence detection and cloud computing -- processing thousands of tests per hour while delivering accurate, digitally verifiable results to a test taker’s mobile device within 5 minutes. To learn more, visit FluroTest.com For all investor inquiries: MarketSmart Communications Inc. 1-877-261-4466 Info@marketsmart.ca For general inquiries: FluroTech Ltd. Danny Dalla-Longa Chief Executive Officer 403.680.0644 info@flurotest.com Cautionary Statement Regarding Forward-Looking Information This news release contains "forward-looking information" within the meaning of Canadian securities legislation. Forward-looking information generally refers to information about an issuer’s business, capital, technology or operations that is prospective in nature, and includes future-oriented financial information about the issuer’s prospective financial performance or financial position. The forward-looking information in this news release includes disclosure about the ability of the Company’s testing devices to accurately and quickly detect COVID-19 and to process large numbers of samples in short time frames, the benefits of and demand for the Company’s testing devices, its efforts to obtain approval of the FDA and Health Canada, its potential partnership with a major U.S. based healthcare system and finalizing plans to conduct clinical trials and its intent to amalgamate with FluroTest Systems Ltd which owns a 95% interest in FluroTest LLC. The Company made certain material assumptions, including but not limited to prevailing market conditions and general business, economic, competitive, political and social uncertainties, the ability to obtain FDA and Health Canada approvals, the demand for its COVID-19 testing devices and their ability to perform as expected, its potential partnership with a major U.S. based healthcare system and finalizing plans to conduct clinical trials and its intent to amalgamate with FluroTest Systems Ltd which owns a 95% interest in FluorTest LLC and to obtain the regulatory approvals required in connection with the same, to develop the forward-looking information in this news release. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Actual results may vary from the forward-looking information in this news release due to certain material risk factors described in the Corporation’s Annual Information Form under the heading “Risk Factors”, the failure to develop and commercialize its testing devices in a timely manner or at all, the failure to recognize the anticipated benefits from the devices, the failure to obtain FDA or Health Canada approval for its products, the risk that regulatory approvals will not be received and the risk that changing circumstances will result in the decrease in demand for FluroTest’s products. The Company cautions that the foregoing list of material risk factors and assumptions is not exhaustive. The Company assumes no obligation to update or revise the forward-looking information in this news release, unless it is required to do so under Canadian securities legislation. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or the securities laws of any state and may not be offered or sold within the United States or to or for the benefit or account of U.S. persons, absent such registration or an applicable exemption from such registration requirements.

    • FluroTech and Hudson Robotics Begin Pandemic Response Unit Pre-Production
      GlobeNewswire

      FluroTech and Hudson Robotics Begin Pandemic Response Unit Pre-Production

      CALGARY, Alberta, Feb. 19, 2021 (GLOBE NEWSWIRE) -- FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) (“FluroTech” or the “Company”), a leading developer of spectroscopy-based technology, together with joint venture FluroTest, LLC (“FluroTest”), a first-mover in surge-scale rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today announced that pre-production development of three functioning pandemic defense platform systems are now underway with laboratory robotics automation partner, Hudson Robotics. These units will be used to pilot automated testing protocols that facilitate point-of-service, rapid testing of individuals with high-speed, high throughput functionality, providing COVID-19 testing results within minutes instead of days. The systems are designed to be portable, and will be deployed for controlled clinical, customer, and field trials over the coming months. Hudson Robotics, founded in 1983, is a market leader with a long-standing history in laboratory automation. Located in Springfield, New Jersey, Hudson Robotics is a leader in microplate automation, laboratory robotics, liquid handling and customized software-driven laboratory automation solutions for life-science research. The company provides tools that can be used in areas such as drug discovery, clinical research and pharmaceutical development, including high throughput screening, proteomics and genomics. A strategic partnership with FluroTest was announced November 20, 2020. “Hudson is thrilled to partner with FluroTech and help bring this important and state-of-the-art testing system to life,” said Bruce Jamieson, Vice President Marketing & Sales, Hudson Robotics. “Pre-production units are essential to test and optimize for commercial production. Integrating automated systems into a portable lab environment is a major step forward, as we’re able to perform significantly more tests in over less time.” “We continue to execute and our direction is clear. Achieving this milestone is the culmination of months of planning and effort,” said Bill Phelan, CEO of FluroTest. “This is an exciting stage of development, where top-notch engineering marries functional and visual platform representation. As we head down the clinical trial path, testing our system viability and helping to validate design in an operational environment are key success factors. I believe the work that we’re doing will lead to the creation of Testing Access Points, ultimately helping society to reopen for work and play.” The data collected will be used to support FluroTest’s submission for Emergency Use Authorization (“EUA”) from the U.S. Food and Drug Administration (“FDA”) and Health Canada for an Interim Order Authorization. Future submissions to additional regulatory bodies around the globe are also being considered. The Company will provide additional updates to the market as appropriate. Readers are cautioned that, although FluroTest has achieved proof of concept prototype, the testing method and device is still in the early stages of research and development and accordingly FluroTest is not currently making any express or implied claims that the technology can, or will be able to, accurately detect the COVID-19 virus. The Platform is in the process of applying for EUA approval from the FDA and Health Canada for an Interim Order Authorization. As announced February 3, 2021 FluroTech has accelerated the financial, regulatory and legal due diligence to complete the transaction with FluroTest shareholders to obtain 95% of the interest in FluroTest. This amalgamation is subject to TSXV conditions and approvals. FluroTech is working to ensure this process is carried out in the most efficient manner possible and will update the market as appropriate. About FluroTech (TSXV: TEST) (OTCQB: FLURF) The goal of FluroTech’s research and technology is to develop detection methods which are sensitive, specific, and easy-to-use. By combining FluroTech’s proprietary spectroscopy-based technology with laboratory robotics automation and cloud computing, FluroTech, through the application of its technology and investment in FluroTest, has created a unique solution addressing the current and future pandemics. Using technology that was first developed at the University of Calgary, the FluroTest SARS-CoV-2 test is designed to identify patients with active virus infection; this is not necessarily the case for most of the currently approved tests that are meant to identify patients with SARS-CoV-2 nucleic acid. FluroTech’s laboratory is led by Dr. Elmar Prenner, the original developer of the technology. Dr. Prenner serves as senior science advisor of FluroTech and brings over 28 years of expertise in fluorescence spectroscopy. To learn more, visit FluroTech.com About FluroTest LLC FluroTest, a first-mover in surge-scale rapid antigen testing for the detection of SARS-CoV2 and other pathogens, is developing a pandemic defense and economic recovery system purpose-built for businesses and special-needs populations requiring fast and highly accurate testing for significant numbers of people. Unlike individual or low-throughput tests, FluroTest’s system is designed to be well-suited for high-traffic, high-risk pandemic environments including schools and colleges, hospitals and large healthcare facilities, athletic stadiums and performance venues, airline and cruise ship terminals, corporate campuses, shopping centers, manufacturing facilities, transportation and distribution hubs, and other large business and retail locations. Created to support executive business continuity efforts, the system combines and leverages the disciplines of robotics automation, biochemistry, fluorescence detection and cloud computing -- processing thousands of tests per hour while delivering accurate, digitally verifiable results to a test taker’s mobile device within 5 minutes. To learn more, visit FluroTest.com For all investor inquiries: MarketSmart Communications Inc. 1-877-261-4466 Info@marketsmart.ca For general inquiries: FluroTech Ltd. Danny Dalla-Longa Chief Executive Officer 403.680.0644 info@flurotest.com Cautionary Statement Regarding Forward-Looking Information This news release contains "forward-looking information" within the meaning of Canadian securities legislation. Forward-looking information generally refers to information about an issuer’s business, capital, technology or operations that is prospective in nature, and includes future-oriented financial information about the issuer’s prospective financial performance or financial position. The forward-looking information in this news release includes disclosure about the ability of the Company’s testing devices to accurately and quickly detect COVID-19 and to process large numbers of samples in short time frames, the benefits of and demand for the Company’s testing devices, its efforts to obtain approval of the FDA and Health Canada, its potential partnership with a major U.S. based healthcare system and finalizing plans to conduct clinical trials and its intent to amalgamate with FluroTest Systems Ltd which owns a 95% interest in FluorTest LLC. The Company made certain material assumptions, including but not limited to prevailing market conditions and general business, economic, competitive, political and social uncertainties, the ability to obtain FDA and Health Canada approvals, the demand for its COVID-19 testing devices and their ability to perform as expected, its potential partnership with a major U.S. based healthcare system and finalizing plans to conduct clinical trials and its intent to amalgamate with FluroTest Systems Ltd which owns a 95% interest in FluorTest LLC and to obtain the regulatory approvals required in connection with the same, to develop the forward-looking information in this news release. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Actual results may vary from the forward-looking information in this news release due to certain material risk factors described in the Corporation’s Annual Information Form under the heading “Risk Factors”, the failure to develop and commercialize its testing devices in a timely manner or at all, the failure to recognize the anticipated benefits from the devices, the failure to obtain FDA or Health Canada approval for its products, the risk that regulatory approvals will not be received and the risk that changing circumstances will result in the decrease in demand for FluroTest’s products. The Company cautions that the foregoing list of material risk factors and assumptions is not exhaustive. The Company assumes no obligation to update or revise the forward-looking information in this news release, unless it is required to do so under Canadian securities legislation. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or the securities laws of any state and may not be offered or sold within the United States or to or for the benefit or account of U.S. persons, absent such registration or an applicable exemption from such registration requirements.